Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07280702 · ClinicalTrials.gov registry record · Phase 4
Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease
A Phase 4 study, sponsored by University of Texas Southwestern Medical Center.
- Not yet
- Registry status
- Phase 4
- Development phase
- 128
- Enrollment target
NCT07280702 is a Phase 4 study that has not yet begun recruiting, run by University of Texas Southwestern Medical Center. The registered enrollment target is 128 participants.
The verdict
NCT07280702, a Phase 4 study, has not yet begun recruiting, sponsored by University of Texas Southwestern Medical Center.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 128 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine the effectiveness of adding deucravacitinib to the participant's current Psoriatic Arthritis (PsA) treatment to see if it improves their symptoms and quality of life. This study is exploring a new treatment approach that may help improve control of psoriatic disease by targeting different parts of the disease process. By combining therapies that work together, the goal is to offer better symptom relief with fewer or more manageable side effects than some current treatments.
Interventions
- DRUG Placebo
- DRUG Deucravacitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2026-04-15 |
| Est. Completion | 2027-12-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07280702
The ClinicalTrials.gov registry entry for NCT07280702 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07280702 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07280702 about?
NCT07280702 is a clinical study titled "Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease". The purpose of this research study is to determine the effectiveness of adding deucravacitinib to the participant's current Psoriatic Arthritis (PsA) treatment to see if it improves their symptoms and quality of life. This study is exploring a new treatment approach that may help improve control of...
What is the current status of trial NCT07280702?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 128 participants. The study started on 2026-04-15. Estimated completion is 2027-12-15.
What interventions are being tested in trial NCT07280702?
The interventions under investigation include: Placebo (DRUG), Deucravacitinib (DRUG).
Who is sponsoring clinical trial NCT07280702?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.